Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress
暂无分享,去创建一个
[1] Jian Yu,et al. BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells , 2016, Oncotarget.
[2] Davide Ruggero,et al. New frontiers in translational control of the cancer genome , 2016, Nature Reviews Cancer.
[3] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[4] Jian Yu,et al. Necroptosis: an alternative cell death program defending against cancer. , 2016, Biochimica et biophysica acta.
[5] M. Simon,et al. Oncogenes strike a balance between cellular growth and homeostasis. , 2015, Seminars in cell & developmental biology.
[6] S. Walz,et al. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer. , 2015, Cancer discovery.
[7] Jian Yu,et al. Loss of Caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis , 2015, Cell Death and Disease.
[8] Jian Yu,et al. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction upon 4E-BP1 dephosphorylation , 2015, Oncogene.
[9] N. Sonenberg,et al. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. , 2015, Cancer research.
[10] Liam O'Connor,et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.
[11] M. Grever,et al. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease , 2014, Oncotarget.
[12] Joseph E Chambers,et al. Endoplasmic reticulum stress in malignancy. , 2014, Cancer cell.
[13] N. Rosen,et al. Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.
[14] Jian Yu,et al. Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention , 2013, Current Colorectal Cancer Reports.
[15] C. Hetz,et al. Targeting the unfolded protein response in disease , 2013, Nature Reviews Drug Discovery.
[16] Jian Yu,et al. Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax , 2013, Molecular Cancer Therapeutics.
[17] E. Nakakura,et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors , 2013, Oncogene.
[18] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[19] P. L. Bergsagel,et al. Molecular pathogenesis of multiple myeloma: basic and clinical updates , 2013, International Journal of Hematology.
[20] Jian Yu,et al. Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells , 2013, Molecular Cancer Therapeutics.
[21] S. Peluso,et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. , 2012, Journal of medicinal chemistry.
[22] C. Dang. Links between metabolism and cancer. , 2012, Genes & development.
[23] Stephen L. Abrams,et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways , 2011, Journal of cellular physiology.
[24] Vanesa Fernández-Majada,et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation , 2011, Nature.
[25] M. Grever,et al. Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells , 2011, The AAPS Journal.
[26] Z. Jehan,et al. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. , 2011, The American journal of pathology.
[27] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[28] R. Hakem,et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice , 2011, Nature.
[29] D. Ron,et al. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress , 2011, Nature Cell Biology.
[30] F. Khuri,et al. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. , 2010, Neoplasia.
[31] Jian Yu,et al. Mitochondrial signaling in cell death via the Bcl-2 family , 2010, Cancer biology & therapy.
[32] A. Hinnebusch,et al. Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.
[33] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[34] A. Ashkenazi. Targeting the extrinsic apoptosis pathway in cancer. , 2008, Cytokine & growth factor reviews.
[35] B. Hwang,et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. , 2007, Anticancer research.
[36] S. Cory,et al. The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.
[37] R. Youle,et al. Role of Bax and Bak in mitochondrial morphogenesis , 2006, Nature.
[38] A. Kinghorn,et al. Silvestrol regulates G2/M checkpoint genes independent of p53 activity. , 2006, Anticancer research.
[39] Jian Yu,et al. PUMA Sensitizes Lung Cancer Cells to Chemotherapeutic Agents and Irradiation , 2006, Clinical Cancer Research.
[40] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[41] Kevin D. Nullmeyer,et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. , 2005, Cancer research.
[42] J. Adams. The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.
[43] G. Cordell,et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. , 2004, The Journal of organic chemistry.
[44] Jian Yu,et al. Apoptosis in human cancer cells , 2004, Current opinion in oncology.
[45] Jian Yu,et al. Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells , 2003, Cancer biology & therapy.
[46] K. Kinzler,et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] K. Kinzler,et al. PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.
[48] K. Kinzler,et al. Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.
[49] M. Schapira,et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. , 2000, Molecular cell.
[50] D. Ron,et al. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase , 1999, Nature.
[51] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[52] V. Michels. The Genetic Basis of Human Cancer , 1999 .
[53] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.